July 2024 in “Medical alphabet” In this case report, a 9-year-old with alopecia areata experienced full hair regrowth after six months of oral tofacitinib, with no recurrence or significant side effects for a year post-treatment.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.
11 citations
,
April 2015 in “EBioMedicine” This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.
3 citations
,
June 2025 in “Archives of Dermatological Research” In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.
June 2026 in “Journal of Cosmetic and Regenerative Medicine” This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.